Paul leads Oncology Translational Research at Pfizer with responsibility for Translational Pharmacology, Tumor Morphology, Clinical Research Lab, Translational Leads and Biomarker Assay Specialists in early clinical development as well as Computational Biology spanning research through late development. Paul joined Agouron Pharmaceuticals (now Pfizer) in 1994 as a computational chemist to build innovative tools for structure-enabled drug discovery, then supported projects in Oncology, Virology and CNS from 1998-2001. From 2001-2005, Paul formed a Bioinformatics Group and co-led Molecular Design, helped create the La Jolla Obesity & Diabetes organization while leading a drug discovery team to nominate threes clinical candidates. Starting in 2005, Paul built the Oncology Computational Biology group and led an interdisciplinary group of scientists focused on Oncology Pathways prior to assuming the role as Head of Translational Research in 2013.
The session will discuss how biopharma companies are implementing new interpretable semantic AI technologies (combining AI/ML and knowledge graphs) to continuously update knowledge based on vast amounts research and clinical data. We will focus on applications in drug discovery and in clinical trials.